Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 7/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678405 | 0.83 | KDM4E (0.37) | GPR35TDP1POLBL3MBTL1KDM4E | |
| SCHEMBL16212934 | 0.78 | KDM4E (0.49) | TDP1POLBKDM4EPKMMEN1 | |
| SCHEMBL5154551 | 0.77 | ALDH1A1 (0.49) | GPR35TDP1POLBL3MBTL1KDM4E | |
| SCHEMBL3836429 | 0.77 | POLB (0.55) | GPR35TDP1POLBL3MBTL1KDM4E | |
| SCHEMBL14100164 | 0.76 | ALDH1A1 (0.40) | GPR35TDP1POLBL3MBTL1KDM4E | |
| SCHEMBL2808786 | 0.76 | GSK3B (0.50) | GPR35TDP1POLBL3MBTL1KDM4E | |
| SCHEMBL27363412 | 0.76 | GPR35 (0.46) | GPR35TDP1POLBL3MBTL1KDM4E | |
| Hydrochloric Acid SCHEMBL7810688 | 0.76 | POLB (0.53) | GPR35TDP1POLBL3MBTL1KDM4E | |
| SCHEMBL321098 | 0.76 | GPR35 (0.60) | GPR35TDP1POLBL3MBTL1KDM4E | |
| SCHEMBL10514890 | 0.74 | GPR35 (0.44) | GPR35TDP1POLBL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016265-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| US-9809582-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-07 | — | — | US | disclosed |
| US-20160326147-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-11-10 | — | — | US | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| CN-101279927-A | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| CN-1723192-A | Arylene-carboxylic acid (2-amino-phenyl) -amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-01-18 | — | — | CN | disclosed |
| US-5310752-A | Distamycin A analogs; antitumor agents, viricides | FARMITALIA CARLO ERBA SPA (IT) | 1994-05-10 | — | — | US | disclosed |
| EP-0246868-B1 | SITE SPECIFIC ALKYLATING AGENTS | FARMITALIA CARLO ERBA S.r.l. (IT) | 1992-09-16 | — | — | EP | disclosed |
| US-5049579-A | Antitumor, viricides | FARMITALIA CARLO ERBA, S.R.L. (IT) | 1991-09-17 | — | — | US | disclosed |
| US-5017599-A | Antitumor, antiviral distamycin A analog | FARMITALIA CARLO ERBA, SPA (IT) | 1991-05-21 | — | — | US | disclosed |
| EP-0246868-A1 | Site specific alkylating agents | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016265-A1 | AMINOESTER DERIVATIVES | PDE4A, PDE3A, PDE3B | GPR35 534/4885TDP1 540/4885POLB 1629/4885 |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | GPR35 144/4885TDP1 4014/4885POLB 2094/4885 |
| US-20160326147-A1 | AMINOESTER DERIVATIVES | PDE4A, PDE3A, PDE3B | GPR35 534/4885TDP1 540/4885POLB 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.